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Upregulation of cyclooxygenase-2 (COX-2) and prostaglandin-dependent vascularisation in small adenomatous polyps is an essential
part of colon carcinogenesis. To study the underlying cellular mechanisms, LT97 and Caco2 human colorectal tumour cells not
expressing endogenous COX-2 were exposed to 1mM prostaglandin E2 (PGE2) in their medium. At 30min after addition, expression
of c-fos was stimulated 5-fold and 1.3-fold, respectively, depending on the activation of both extracellular signal-regulated kinase and
p38. The amount of c-jun in nuclear extracts was increased 20% in LT97 cells. Expression of COX-2 was upregulated 1.7-fold in LT97
cells and 1.5-fold in Caco2 2h after prostaglandin (PG) addition by a p38-mediated pathway. The known PGE2 target gene vascular
endothelial growth factor (VEGF) was not modulated. Effects of sustained PGE2 production were studied in VACO235 cells that
have high endogenous COX-2 and in LT97 cells infected with an adenovirus expressing COX-2. Prostaglandin E2 secretion into the
medium was 1–2nM and 250pM, respectively. Expression of both VEGF and c-fos was high in VACO235 cells. In LT97 cells, COX-2
upregulated c-fos expression and c-jun content in nuclear extracts 1.7- and 1.2-fold, respectively, in a PG-dependent way. This shows
that exogenous PGE2 as well as COX-2 overexpression affect signalling and gene expression in a way that enhances tumour
progression.
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Upregulation of cyclooxygenase-2 (COX-2) expression in early
adenomas is an essential prerequisite of colorectal carcinogenesis.
It causes elevated levels of prostaglandins (PGs) in the tissue
and PG-dependent neovascularisation (Eberhart et al, 1994).
Adenomatous polyps regress under therapy with non-steroidal
anti-inflammatory drugs whose main cellular target is COX-2
(DuBois et al, 1996). Mice carrying a hereditary mutation in the
APC gene (min-mice or transgenic DAPC-mice; (de Wind et al,
1998) develop a multitude of intestinal polyps in a COX-2 and
prostaglandin E2 (PGE2)-receptor-dependent way (Sonoshita et al,
2001; Seno et al, 2002; Sunayama et al, 2002). Immunohistochem-
ical analysis of tissue sections shows that much of the COX-2 is
located in connective tissue but not in the epithelial compartment
of the polyps. In the pathology of human colorectal cancer, COX-2
plays a similar role and has become the main target of
chemoprevention in high-risk patients (DuBois et al, 1996; Gupta
and Dubois, 2001). As in the mouse models, COX-2 is mainly
located in the connective tissue of human adenomatous polyps.
This raises the question whether PGs produced in the
microenvironment (fibroblasts, endothelial cells or macrophages)
can in turn affect early premalignant cells and trigger expression
of tumour-associated genes. To answer these questions we have
established the human colonic adenoma cell line LT97 from
microadenomas of a polyposis patient that do not yet express
COX-2 or produce PGE2 (Richter et al, 2001). Tumour-promoting
bile acids have been shown to induce expression of c-fos, COX-2
and vascular endothelial growth factor (VEGF) in these early
human colonic adenoma cells (Jurek et al, 2005). The current
study analysed the following: (1) the cellular effects of exogenous
PGE2 on the expression of COX-2, c-jun and c-fos in LT97 human
colorectal adenoma cells as well as Caco2 colorectal carcinoma
cells that also express little COX-2, (2) the consequences of
sustained COX-2 expression in VACO235 cells that have a high
level of endogenous expression of the enzyme (Willson et al, 1987)
and in LT97 cells infected with a COX-2-expressing adenovirus.
MATERIALS AND METHODS
Tissue culture and exposure to PG
LT97 colon adenoma cells were established by our laboratory
(Richter et al, 2002). They were kept under standard tissue culture
conditions by using Ham F-12 medium containing 20% L-15
medium, 2% FCS, 10mgml
 1 insulin, 2 10
 10 M triiodotyronine,
2mgml
 1 transferrin, 1mgml
 1 hydrocortisone, 5 10
 9 M Na-
selenite and 30ngml
 1 epidermal growth factor (EGF). Under these
conditions, LT97 cells have a doubling time of B96h. VACO235
adenoma cells were a gift from Willson et al (1987) and were cul-
tured with minimal essential medium (MEM) supplemented with
2% FCS, 10mgml
 1 insulin, 2 10
-10 M triiodotyronine, 2mgml
 1
transferrin, 1mgml
 1 hydrocortisone, 5 10
 9 M Na-selenite and
30ngml
 1 EGF. Their doubling time was B60h. Caco2 colorectal
carcinoma cells were obtained from the American Type Culture
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sCollection and propagated in MEM containing 10% FCS with a
doubling time of about 48h. HEK293 cells were a gift of Dr M
Herlyn (Wistar Institute). They were cultivated in RPMI medium
containing 10% FCS.
Prostaglandin E2 or vehicle was added to LT97 cells 96h, and to
Caco2 cells 48h, after plating. For inhibition of COX-2, SC236
(Searle Skokie, IL, USA) was added concomitantly with the PG in a
concentration of 1mM that did not affect proliferation of LT97 cells.
The kinase inhibitors U0126 and PD169316 were purchased from
Calbiochem (San Diego, CA, USA)
Cell number
The cell number was determined by neutral red uptake during
a period of 2h from serum-free MEM containing 50mgml
 1 of the
dye, which was taken up into the lysosomes of viable cells. After
removal of excess dye by washing with PBS, neutral red taken up
into the cells was extracted with 1% acetic acid in 70% ethanol.
Absorbance was measured at 562nm using a plate reader.
Construction of adenoviral vectors expressing COX-2
The entire coding region of human COX-2 was obtained by ampli-
fication with PFU DNA polymerase (Stratagene, La Jolla, CA, USA)
using primers 50-TAAGTCGACCGCTCGGATGCTCG-30 and 50-G A
CTCTAGACTACAGTTCAGTCGAACG-30 from the cDNA of EST
clone CS0DK012YH07 (Invitrogen, CA, USA) from a human cervix
carcinoma cell line. The PCR product was first cloned into pCR2.1-
TOPO vector (Invitrogen) and further transferred via restriction
with EcoRI into the expression vector pCMV-SPORT6 (Invitrogen)
in sense orientation. The recombinant protein from the sense
construct was expressed in vitro from the SP6 promoter as a
70kDa protein using the TNT-SP6 Coupled Reticulocyte Lysate
System (Promega, Mannheim, Germany). The cDNA fragments
were further subcloned with the restriction enzymes HindIII and
KpnI into the pShuttle-CMV (Stratagene).
The adenoviral expression vector Ad-COX-2 was created by a
double-recombination event in bacteria between cotransformed
adenoviral plasmid pAdEasy-1 (Stratagene) and shuttle vector
pShuttle-CMV based on the method described by He et al (1998).
Briefly, the shuttle vector was linearised with PmeI, gel purified
and cotransformed into BJ5183 cells by electroporation. Single
clones were selected and confirmed by PacI digestion of plasmid
DNA. Plasmids from correct clones were amplified by transforma-
tion of XL10 cells (Stratagene) followed by DNA maxiprep (Qiagen,
Helden, Germany). The adenoviral DNA of Ad-COX-2 was linear-
ised with PacI, heat-inactivated, ethanol-precipitated and used for
transfection of the packaging cell line HEK293 with Lipofect2000
(Invitrogen). Shuttle vector without any insert was used to
construct control virus (Ad-co). Transfected cells were incubated
for 7–10 days until cytopathic effect appeared. Primary virus was
harvested, amplified and purified using a double CsCl gradient.
Virus titer was determined by a standard plaque assay using
HEK293 cells.
Determination of gene expression
Total RNA was isolated with TRIZOL (Gibco Life Technologies,
Paisley, UK) according to the manufacturer’s instructions. RNA
(2mg) was used to synthesise cDNA by reverse transcription using
random hexamer primers and M-MLV reverse transcriptase
(Sigma, St Louis, MO, USA).
Genes of interest were amplified from cDNA samples by
standard PCR cycles of 1min denaturation (941C), 30s annealing
and 1min synthesis at 721C. Reaction products were separated on
6% polyacrylamide gels and stained with 0.5mgml
 1 ethidium-
bromide. For quantitation, GelDoc 2000 system and the software
Quantity One 4.2.1. (Bio-Rad Laboratories, USA) were used.
Linearity of amplification was determined at the range of 25–35
cycles for target genes and 18–25 cycles for GAPDH to chose the
adequate number of cycles for each analysis. For the number of
cycles chosen, dose dependency was confirmed by using increasing
amounts of cDNA. Primer sequences, annealing temperatures and
number of cycles are listed in Table 1.
Quantification of gene expression by real-time PCR
c-fos, COX-2 and VEGF were amplified from cDNA samples by
real-time PCR using TaqMan assays on an ABI PRISM 7000
Thermocycler (Applied Biosystems, Foster City, CA, USA). After
denaturation for 10min at 951C, 40 cycles of 15s denaturation
(951C) and 60s annealing and synthesis at 601C were performed
using TaqMan Assay-on-Demand kits (Table 2) and TaqMan
Universal PCR Master Mix. Quantitative assessment was per-
formed using the DDCT method.
Western blotting
Cells were dislodged from the culture plate by using a cell scaper,
collected by centrifugation and washed 2  with icecold PBS. Cell
pellets were homogenised in RIPA-buffer (50mM Tris/HCl pH 7.4;
Table 1 Polymerase chain reaction conditions for assessment of gene expression
Gene Primer sequences Annealing temperatures Cycles
GAPDH
Sense 50-CGGGAAGCTTGTGATCAATGG-30 551C2 2
Antisense 50-GGCAGTGATGGCATGGACTG-30
c-fos
Sense 50-CCTGTCAAGAGCATCAGCAGCATGG-30 601C2 9
Antisense 50-GAGTACAGGTGACCACCGGAGTGC-30
COX-2
Sense 50-TTCAAATGAGATTGTGGGAAAAT-30 551C3 2
Antisense 50-AGATCATCTCTGCCTGAGTA-30
VEGF
Sense 50-CTGCTGTCTTGGGTGCATTG-30 531C3 0
Antisense 50-CACCGCCTCGGCTTGTCACAT-30
Table 2 TaqMan assays for quantification of gene expression
Gene Assay ID (ABI) NCBI entry Reporter Quencher
GAPDH Hs99999905_m1 NM_002046 FAM NFQ
c-fos Hs00170630_m1 NM_005252 FAM NFQ
COX-2 Hs00153133_m1 NM_000963 FAM NFQ
VEGF Hs00173626_m1 NM_003376 FAM NFQ
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NaN3,2 0mlml
 1 Complete Protease Inhibitor (Roche Diagnostics,
Vienna, Austria), 500mM sodium vanadate and 5mM sodium
fluoride). The insoluble fraction was removed by centrifugation
for 15min at 41C and 14500r.p.m. A total of 20mg protein per lane
were analysed by electrophoresis on 12 or 15% polyacrylamide
gels and transfered to PVDF-membranes. Membranes were probed
with antibodies directed against extracellular signal-regulated
kinase (ERK) (1:10000; Upstate Biotechnology, Lake Placid, NY,
USA) and p-ERK (1:5000; Sigma, St Louis, MO, USA), p38
(1:1000; Santa Cruz, Santa Cruz, CA, USA) and p-p38 (1:1000;
Sigma) and COX-2 (1:200; Transduction Laboratories). Secondary
horseradish-peroxidase-coupled antibodies were diluted 1:5000
and detected by the Super Signal West Pico Western blotting
detection system (Pierce, Rockford, IL, USA).
DNA-binding c-jun in the nucleus
DNA-binding c-jun was determined from nuclear extracts using the
Mercury Transfector kit (Clontech, Palo Alto, CA, USA) according
to the manufacturer’s instructions. In short, nuclei were isolated
from about 1–5 10
7 cells lysed in 10mM HEPES pH 7.9
containing 1.5mM MgCl2,1 0 m M KCl, 10mM DTT and 0.1mlml
 1
Complete Protease-Inhibitor (Roche). Nuclei were extracted using
20mM HEPES pH 7.9 containing 1.5mM MgCl2, 0.42 M NaCl, 0.2mM
EDTA, 10mM DTT, 0.1mlml
 1 Complete Protease-Inhibitor and
25% (vv
 1) glycerol. A total of 30mg extracted protein was bound
to 96-well plates coated with c-jun-binding oligonucleotide. After
washing the plates and blocking of unspecific binding sites, c-jun
was detected using an ELISA detection reaction.
PG production
Cells were left to secrete PGE2 for 24h after addition of 10mM
arachidonic acid substrate into the medium. Prostaglandin E2
secreted during this period was determined using an indirect
ELISA kit purchased from Caymen Chemicals (Ann Arbor, MI,
USA) according to the manufacturer’s instructions.
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Figure 1 Stimulation of adenoma cell growth by PGE2. A measure of
0.1, 1 and 5mM PGE2 was added to the culture medium 2 days after plating
and cell number determined 2, 5 and 8 days later.
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Figure 2 Expression of COX-2 and VEGF in LT97 adenoma and Caco2 carcinima cells. LT97 cells were exposed to 1mM PGE2 and transcripts were
analysed after 30min, 2, 4, and 6h. Expression of COX-2 (A) and VEGF (B) was determined by RT–PCR and PCR products were analysed on 6%
polyacrylamide gels. Quantification of gene expression was obtained by real-time PCR and calculated relative to GAPDH. Values given represent
mean7s.e.m. from three independent experiments. (C, D) LT97 colorectal adenoma cells, (E, F) Caco2 colorectal carcinoma cells, (C, E) COX-2 and (D,
F) VEGF. *Increased above control at Po0.05.
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Stimulation of cell growth by PGE2
Two days after seeding, increasing concentrations of PGE2 were
added to the culture medium of LT97 human colorectal adenoma
cells and cell number was determined at days 2, 5 and 8. Growth
was stimulated by all PG concentrations, with the optimal
concentration at 1mM (Figure 1). Consequently, the 1mM concen-
tration was used for most experiments elucidating signalling
events and gene expression.
Modulation of COX-2 and VEGF gene expression by PGE2
To determine whether exogenous PGs can stimulate COX-2
expression and consequently their own production, LT97 cells as
well as Caco2 colorectal carcinoma cells were exposed to 1mM PGE2
for up to 6h and expression of COX-2 was determined by RT–
PCR. Expression was elevated 2h after PGE2 addition (Figure 2A),
indicating the possibility that a positive feed-back loop of PG-
production is established. Similar but smaller effects were obtained
after addition of 5mM PGE2 (data not shown). In addition, the
expression of VEGF in LT97 cells was analysed from the same
RNAs. From five known splice variants, we could detect two
main forms – VEGF165 and VEGF121; however, no changes in
expression were observed owing to exposure to PGE2 (Figure 2B).
Real-time PCR was performed to obtain reliable quantification
using cDNAs of the 1mM PGE2 groups (Figure 2C and D). The
results showed a 50% increase of COX-2 expression (Figure 2C,
Po0.05). Vascular endothelial growth factor expression was not
increased but rather tendentiously suppressed 4 and 6h after addi-
tion of PGE2 (Figure 2D).
Effects of PGE2 exposure were also measured in Caco2 colorectal
carcinoma cells with similar results: expression of COX-2 increased
28% (Pp0.05) 2h after PG addition (Figure 2E), whereas expres-
sion of VEGF was variable and not significantly increased
(Figure 2F).
Effects on cellular signalling
Expression of c-fos was determined from RNAs isolated after
exposure to PGE2 as described above using quantitative real-time
PCR. Expression was stimulated about 6-fold 30min after addition
of the PGE2 (1mM) after which it rapidly returned to control levels
(Figure 3A). In Caco2 cells c-fos induction by the PG was smaller.
We did, however, observe significant increases both 30min and 2h
after addition of PGE2 (Figure 3B).
Induction of c-jun was analysed from nuclear extracts of LT97
adenoma cells using c-jun-binding oligonucleotides and a specific
c-jun antibody in an ELISA format. Addition of PGE2 to the
cultures stimulated c-jun binding to the promoter sequence by
about 20% (Po0.05; Figure 3C).
For analysis of signalling kinases, LT97 cells were homogenised
in RIPA buffer after 0.5, 2 and 4h of exposure to 1mM PGE2.
Proteins were separated by SDS–PAGE and phosphorylation of
ERK and p38 was analysed using phosphorylation-specific anti-
bodies. We observed increased phosphorylation of both signalling
kinases (representative Western blot shown in Figure 4A and B).
Semi-quantification of band intensities from four independent
experiments demonstrates a 2–7-fold increase of ERK phosphory-
lation from 30min to 4h after PGE2 addition (Figure 4A). Phos-
phorylation of p38 was increased about 2-fold 30min and 2h after
PGE2 addition. At the 4h time point, phosphorylation in the control
group had reached a level similar to the PGE2 group (Figure 4B).
To investigate whether the activation of ERK was essential for
the induction of COX-2 and c-fos expression, the mitogen-
activated protein kinase inhibitor U0126 was added to the culture
medium together with the PG and COX-2 and c-fos expression
assessed by standard RT–PCR. The inhibitor prevented induction
of c-fos expression, whereas it did not affect expression of COX-2
(Figure 4C). Addition of PD169316, an inhibitor of p38 signalling,
blocked expression of COX-2 as well as c-fos (Figure 4D).
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Figure 3 Induction of c-fos and c-jun by PGE2. Expression of c-fos was
determined from the same cDNA preparation used in Figure 2 and
quantified relative to GAPDH (A) LT97 cells, (B) Caco2 cells. c-jun protein
was quantified from nuclear extracts obtained from LT97 cells by using an
ELISA format detecting DNA-binding of c-jun (C). Values given represent
mean7s.e.m. from three independent experiments. *Increased above
control at Po0.05.
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cultures
The data described above indicate that PGE2 present in the
microenvironment is capable of triggering COX-2 expression and
consequently sustained PG production by the adenoma cells
themselves that potentially have even more pronounced effects on
the expression of tumour progression-associated genes. VACO235
are villous adenoma cells that highly express COX-2 and secrete
PGE2 up to a concentration of 1–2nM into their culture super-
natant (Willson et al, 1987; Richter et al, 2001). Expression of
VEGF and c-fos in these cells was analysed by RT–PCR and found
to be higher than that of LT97 cells (Figure 5).
To obtain cells with high or low COX-2 expression in the same
genetic background, we used an adenoviral vector expressing
COX-2 under the control of a CMV promoter. LT97 cells were
infected with 10 multiplicity of infection of the virus. At 24h after
infection, COX-2 protein could be detected in the infected cells
(Figure 6A) and PG secretion into the medium increased from
o15pM to about 250pM PGE2 (Figure 6B). Prostaglandin produc-
tion could be completely inhibited by the specific COX-2 inhibitor
SC236 (Figure 6B). Cell growth was not affected by the transfection
(data not shown).
We then proceeded to analyse gene expression and signalling
kinases in LT97 adenoma cells carrying a COX-2 adenovirus
(LT97-COX-2 cells) in the presence and absence of SC236 and
consequently, in the absence and presence of PG. Expression of the
COX-2 target gene VEGF was highly variable as shown by the large
standard deviation (Table 3). Expression of c-fos on the other hand
was increased 1.7-fold in a PGE2-dependent manner (Figure 6C).
Increased binding of c-jun from nuclear extracts to promoter DNA
was induced about 20% (Pp0.05, Figure 6D).
Activation of ERK and p38 signalling was analysed by Western
blot as described above and both kinases were activated in cells
infected with the COX-2 virus. Although ERK phosphorylation was
stimulated in a PG-dependent manner, phosphorylation of p38 in
cells infected with the COX-2 virus was not affected by the COX
inhibitor (Figure 7A and B).
DISCUSSION
Histological examination of polyps in the min-mouse model
suggested that COX-2 expression and PG production takes place
primarily in the connective tissue. Sonoshita et al (2002) have
identified fibroblasts and endothelial cells as the main source,
whereas elevated COX-2 protein in the epithelial compartment was
not observed. It has to be assumed therefore that at this early stage
of tumour development, adenoma cells are subject to elevated
levels of prostaglandin produced locally in the tumour micro-
environment. This paper has investigated the effects this may have
on tumour progression.
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Figure 4 Activation of signalling kinases. Activation of the signalling kinases ERK (A) and p38 (B) in LT97 adenoma cells was analysed by Western blotting
with phosphorylation-specific antibodies. Band intensities were semi-quantified using the Image Quant software. The results represent the mean7s.e.m.
from three independent experiments. *Larger than control at the same time point at Po0.05. U0126 or PD169316 were added to the culture medium
concomitantly with the PG to inhibit phosphorylation of ERK and p38, respectively. RNA was isolated after 30min and expression of c-fos (C) and COX-2
(D) was analysed by standard RT–PCR. Band intensities were semi-quantified using the Image Quant software. The results represent the mean7s.e.m. from
three independent experiments. *Larger than control at the same time point at Po0.05, # smaller than PG group at Po0.05.
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adenoma cells and Caco2 colorectal carcinoma cells that express
only minimal amounts of COX-2 and produce little PGE2 (Richter
et al, 2001). Exposure to PGE2 stimulated growth of the adenoma
cells with an optimal concentration of 1mM as well as in the
Caco2 cells (Pai et al, 2002). As compared to the amounts of PG
secreted by COX-2-expressing cells into their culture medium, this
concentration is very high, which may explain why smaller effects
were observed with the highest concentration (5mM). A similar
tendency to inhibit proliferation has been observed in a rat colon
tumour model after treatment with 16,16-dimethyl-PGE2. Both in
the normal colonic mucosa and in the tumour, a reduction of
mitotic index was observed in the highest PG-dose group mediated
by an increase of cAMP (Tutton and Barkla, 1980). Prostaglandin
E2 effects in min-mice are mediated by the PG receptors EP2 and 4,
which signal via cAMP. Therefore, the smaller effects we observed
at the 5mM concentrations in our study may well be caused by
the higher production of cAMP. However, it is difficult to assess
the local tissue concentration of PGE2 in the in vivo situation so
that the conclusions cannot be taken further at this point.
Single doses of PGE2 also induced expression of COX-2 and
c-fos and stimulated signalling kinases in a time-dependent
way. Maximum effects were observed after 30min (c-fos, c-jun,
signalling kinases) to 2h (COX-2, signalling kinases). At later time
points, the effects diminished as was expected from a single dose
of an effector with limited chemical stability. The situation in vivo
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Figure 5 Gene expression pattern in adenoma cells. RNA was isolated
from VACO235 and LT97 adenoma cell cultures at about 50% confluency.
Expression of COX-2, VEGF and c-fos was determined by RT–PCR.
Expression of GAPDH was determined for standardisation. Polymerase
chain reaction products were analysed on 6% acrylamide gels. The figure
shows a composite of two individual analyses each with its separate
GAPDH control.
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Figure 6 Gene expression in LT97 adenoma cells overexpressing COX-
2. LT97 cells were infected with an adenoviral vector expressing COX-2.
Control groups were infected with control viruses containing no ectopic
gene and cells exposed to the COX-2 inhibitor SC236. (A) Cells were
homogenised in RIPA buffer and COX-2 protein analysed by Western
blotting. (B) Prostaglandin E2 secretion into the medium was determined
by ELISA. (C) RNA was isolated from control transfectants and COX-2-
LT97 cells in the presence and absence of the COX-2 inhibitor SC236 and
c-fos expression was analysed by standard RT–PCR. Polymerase chain
reaction products were seperated on 6% acrylamide gels and band
intensities were semi-quantified using the Image Quant software. The
results represent the mean7s.e.m. from three independent experiments.
*Increased above control at Po0.05. (D) c-jun in nuclear extracts from
control cultures and COX-2-LT97 cells in the presence and absence of
SC236 was quantified as described in Figure 2.
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sis much better reflected by cultures overexpressing COX-2 so
that they produce less PG, but do so continually over time. In
our study, this affected gene expression and signalling events in a
similar manner but over at least 24h.
In detail, addition of PGE2 to tumour cell cultures upregulated
expression of COX-2 and consequently stimulated the endogenous
production of PG in both LT97 and Caco2 cells. In LT97 cells, this
event was preceeded by expression of c-fos and an increase of
c-jun in the nucleus and dependent on activation of the p38
signalling kinase.
Of VEGF, a crucial PGE2 target gene in colonic polyps (Seno
et al, 2002), two main splice variants were found representing the
main products identified in colorectal tumour cells by Uthoff et al
(2002). Unexpectedly, no stimulation of VEGF expression could be
observed in both LT97 and Caco2 cells.
As a model for advanced adenomas VACO235 were used. These
cells express high levels of COX-2 and produce as much as 1–2nM
PGE2 within 24h. Their VEGF expression was higher than that
of LT97 cells. As PG production could not be completely blocked
by SC236, a highly specific COX-2 inhibitor (Richter et al, 2001),
we cannot prove that the effect was PG dependent. Neither could
stimulation of VEGF expression be confirmed using LT97 cells
overexpressing COX-2 from an adenoviral vector. This may be due
to the much smaller amount of PG produced from the transgene in
LT97 cultures (250pM). However, we cannot preclude unrelated
causes. Although this seems to contradict the hypothesis that PGs
act as an angiogenic switch (Seno et al, 2002; Sunayama et al,
2002), it has to be kept in mind that the adenoma cells are not the
only cells capable of response to PGE2 present in an adenomatous
polyp. In polyps in vivo PG can exert paracrine effects on
fibroblasts, or endothelial cells, as both cell types have been shown
to be responsive in other models (Gupta and Dubois, 2001; Pai
et al, 2001; Trompezinski et al, 2001).
The strong expression of COX-2 in VACO235 cells also corre-
lated with higher expression of c-fos. In this case, upregulation was
confirmed by use of LT97 cells overexpressing COX-2. Inhibition
by 1mM SC236 demonstrated that the effect was PG dependent. In
addition, c-jun protein in the nucleus was increased in a PGE2-
dependent manner. Induction of c-fos has also been achieved by
tumour-promoting but not by non-promoting bile acids (Jurek
et al, 2005). Stimulation of c-fos and c-jun together indicates
activation of AP1 which is frequently observed following exposure
to tumour-promoting compounds in the colon as well as the
skin (Qiao et al, 2000; Angel et al, 2001; Bachelor and Bowden,
2004) and is regarded as a therapeutic target (Suto et al, 2004).
Expression of c-fos was dependent on the activation of both
ERK and p38 in cells exposed to PGE2. This indicates that
more than one stimulus is necessary for induction of c-fos, which
was also shown after exposure to bile acids (Qiao et al, 2000). In
our study, both kinases were also activated in COX-2-over-
expressing cells, but p38 activation could not be shown to be PG
dependent.
In summary, we provide evidence that both PGE2 from the
microenvironment and upregulation of COX-2 affect signalling
and gene expression in human colorectal adenoma cells in a way
that enhances tumour progression by both autocrine and paracrine
mechanisms.
Table 3 Relative expression VEGF in COX-2-LT97 cells
Experimental group VEGF (% of uninfected control)
Ad-co 112.3720.7
Ad-co+SC236 107.675.3
Ad-COX 2 236.7748.7
Ad-COX 2+SC236 333.07155.7
VEGF¼vascular endothelial growth factor; COX-2¼cyclooxygenase-2.
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Figure 7 Activation of signalling kinases in COX-2-overexpressing cells.
Activation of ERK and p38 was analysed from protein lysates from control
cells as well as COX-2-LT97 cells in the presence and absence of SC236.
Band intensities were semi-quantified using the Image Quant software. The
results represent the mean7s.e.m. from three independent experiments.
*Larger than control at Po0.05.
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